The clock is ticking on schizophrenia: a study protocol for a translational study integrating phenotypic, genomic, microbiome and biomolecular data to overcome disability.

Autor:	Mercuriali G; IRCCS San Raffaele Scientific Institute, Milan, Italy., Lodde L; Unit of Psychiatry, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.; Unit of Clinical Psychiatry, University Hospital Agency of Cagliari, Cagliari, Italy., Paribello P; Unit of Psychiatry, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.; Unit of Clinical Psychiatry, University Hospital Agency of Cagliari, Cagliari, Italy., Sapienza J; IRCCS San Raffaele Scientific Institute, Milan, Italy., Corona A; Unit of Psychiatry, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.; Unit of Clinical Psychiatry, University Hospital Agency of Cagliari, Cagliari, Italy., Ave C; IRCCS San Raffaele Scientific Institute, Milan, Italy., Pacini D; Unit of Psychiatry, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.; Unit of Clinical Psychiatry, University Hospital Agency of Cagliari, Cagliari, Italy., Nocera D; IRCCS San Raffaele Scientific Institute, Milan, Italy., Corrias C; Unit of Psychiatry, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.; Unit of Clinical Psychiatry, University Hospital Agency of Cagliari, Cagliari, Italy., El Kacemi S; Unit of Psychiatry, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.; Unit of Clinical Psychiatry, University Hospital Agency of Cagliari, Cagliari, Italy., D'Incalci M; IRCCS San Raffaele Scientific Institute, Milan, Italy., Frau I; Unit of Psychiatry, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.; Unit of Clinical Psychiatry, University Hospital Agency of Cagliari, Cagliari, Italy., Monzani E; IRCCS San Raffaele Scientific Institute, Milan, Italy., Valtorta F; IRCCS San Raffaele Scientific Institute, Milan, Italy.; School of Medicine, Vita-Salute San Raffaele University, Milan, Italy., Congiu D; Department of Biomedical Science, Section of Neuroscience and Clinical Pharmacology, University of Cagliari, Monserrato, Cagliari, Italy., Meloni A; Department of Biomedical Science, Section of Neuroscience and Clinical Pharmacology, University of Cagliari, Monserrato, Cagliari, Italy., Scherma M; Department of Biomedical Science, Section of Neuroscience and Clinical Pharmacology, University of Cagliari, Monserrato, Cagliari, Italy., Fadda P; Department of Biomedical Science, Section of Neuroscience and Clinical Pharmacology, University of Cagliari, Monserrato, Cagliari, Italy., Dedoni S; Department of Biomedical Science, Section of Neuroscience and Clinical Pharmacology, University of Cagliari, Monserrato, Cagliari, Italy., Siddi C; Department of Biomedical Science, Section of Neuroscience and Clinical Pharmacology, University of Cagliari, Monserrato, Cagliari, Italy., Sut S; Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy., Dall'Acqua S; Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy., Nasini S; Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy., Barzon B; Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy., Squassina A; Department of Biomedical Science, Section of Neuroscience and Clinical Pharmacology, University of Cagliari, Monserrato, Cagliari, Italy., Cavallaro R; IRCCS San Raffaele Scientific Institute, Milan, Italy.; School of Medicine, Vita-Salute San Raffaele University, Milan, Italy., Manchia M; Unit of Psychiatry, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.; Unit of Clinical Psychiatry, University Hospital Agency of Cagliari, Cagliari, Italy.; Department of Pharmacology, Dalhousie University, Halifax, NS, Canada., Pisanu C; Department of Biomedical Science, Section of Neuroscience and Clinical Pharmacology, University of Cagliari, Monserrato, Cagliari, Italy., Bosia M; IRCCS San Raffaele Scientific Institute, Milan, Italy.; School of Medicine, Vita-Salute San Raffaele University, Milan, Italy., Comai S; IRCCS San Raffaele Scientific Institute, Milan, Italy.; Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy.; Department of Biomedical Sciences, University of Padua, Padua, Italy.; Department of Psychiatry, McGill University, Montreal, QC, Canada.
Jazyk:	angličtina
Zdroj:	Frontiers in psychiatry [Front Psychiatry] 2024 Oct 30; Vol. 15, pp. 1451678. Date of Electronic Publication: 2024 Oct 30 (Print Publication: 2024).
DOI:	10.3389/fpsyt.2024.1451678
Abstrakt:	Background: Shared biological factors may play a role in both the cognitive deficits and the increased prevalence of metabolic syndrome observed in individuals with Schizophrenia (SCZ). These factors could entail disturbances in tryptophan (Trp) to both melatonin (MLT) and kynurenine (Kyn) metabolic pathways, as well as inflammation and alterations in the gut microbiome composition. Methods: The present research project aims to investigate this hypothesis by recruiting 170 SCZ patients from two different recruitment sites, assessing their cognitive functions and screening for the presence of metabolic syndrome. Additionally, we plan to assess the impact of a 3-month cognitive remediation therapy on 30 of these patients. We will analyze clinical data alongside serum biomarkers and gene expression related to the Trp- to MLT and Kyn metabolic pathways, markers of inflammatory and composition of the gut microbiome. The association between Trp-MLT-Kyn levels, expression levels of selected genes, inflammatory markers and clinical phenotypes will be analyses in the context of general linear models. Discussion: This project has the potential to identify some typical SCZ symptomatic clusters that will be more stringently associated with variations in the Trp-MLT-Kyn/inflammatory system and with a better response to cognitive remediation therapy. Moreover, in a future perspective, it may highlight a group of patients who may benefit from a pharmacological treatment aiming at reinstating the physiological Trp to MLT and Kyn system. Therefore, it has the potential to move research toward a personalized approach for SCZ management. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision. (Copyright © 2024 Mercuriali, Lodde, Paribello, Sapienza, Corona, Ave, Pacini, Nocera, Corrias, El Kacemi, D'Incalci, Frau, Monzani, Valtorta, Congiu, Meloni, Scherma, Fadda, Dedoni, Siddi, Sut, Dall’Acqua, Nasini, Barzon, Squassina, Cavallaro, Manchia, Pisanu, Bosia and Comai.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu